Gut Metabolite From Microbes Tied to Alzheimer’s Pathology
A new study identifies imidazole propionate (ImP), a metabolite produced by certain gut bacteria, as a potential link between the microbiome and Alzheimer's disease by weakening the blood-brain barrier and promoting amyloid beta plaques and tau changes. In humans, higher ImP levels correlate with faster cognitive decline and elevated Alzheimer’s biomarkers; in mouse models, ImP worsens disease features. ImP-producing bacteria are present in many people but not highly abundant, and susceptibility depends on multiple factors. Targeting ImP or its production could become a therapeutic strategy rather than eliminating the bacteria.
